- 1 Kroegel C. Asthma bronchiale. Pathogenetische Grundlagen, Diagnostik und Therapie,
2. überarbeitete und erweiterte Auflage. Stuttgart, New York: Thieme 2002
- 2
Kroegel C, Foerster M, Workalemahu G. et al .
Grundlagen der asthmatischen Entzündung.
Z ärztl Fortbild Qualitätssich.
2001;
95
677-683
- 3
Presta L, Lahr S, Shields R. et al .
Humanization of an antibody directed against Immunoglobulin E.
J Immunol.
1993;
151
2623-2632
- 4
Banyash M, Kerhy M, Eshar Z.
Anti-IgE monoclonal antibodies directed at the Fcε-receptor binding site.
Mol Immunol.
1988;
25
705-711
- 5
Coyle A J, Wagner K, Bertrand C. et al .
Central role of immunoglobulin (Ig) E in the induction of lung eosinophil infiltration
and Th2 cell cytikine production: inhibition by a non-anaphylactogenic anti-IgE antibody.
J Exp Med.
1996;
183
1303-1310
- 6
Fox J A, Hotaling T E, Struble C. et al .
Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous
administration in cynomolgus monkeys.
J Pharmacol Exp Ther.
1996;
279
1000-1008
- 7
MacGlashan Jr D W, Bochner B, Adelman D. et al .
Down-regulation of FcεRI expression on human basophils during anti-IgE antibody therapy.
J Immunol.
1997;
158
1438-1445
- 8
Corne J, Djukanovic R, Thomas L. et al .
The effect of intravenous administration of a chimeric anti-IgE antibody on serum
IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics.
J Clin Invest.
1997;
99
879-887
- 9
Hochhaus G, Brookman L, Fox H. et al .
Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical
efficacy in the treatment of allergic asthma.
Curr Med Res Opin..
2003;
19
491-498
- 10
Beeh K M, Beier J, Buhl R.
Saisonale Schwankungen des Serum-IgE-Spiegels und deren mögliche Bedeutung für die
Berechnung der therapeutischen Dosis von Omalizumab (rhuMab-E25, anti-IgE).
Pneumologie.
2004;
58
546-551
- 11
Hayashi M, Ohashi Y, Tanaka A. et al .
Suppression of seasonal increase in serum interleukin-5 is linked to the clinical
efficacy of immunotherapy for seasonal allergic rhinitis.
Acta Otolaryngol Suppl.
1998;
538
133-142
- 12
Masamoto T, Ohashi Y, Nakai Y.
Specific immunoglobulin E, interleukin-4, and soluble vascular cell adhesion molecule-1
in sera in patients with seasonal allergic rhinitis.
Ann Otol Rhinol Laryngol.
1999;
108
169-176
- 13
Ohashi Y, Tanaka A, Kakinoki Y. et al .
Serum level of soluble interleukin-2 receptor in patients with seasonal allergic rhinitis.
Scand J Immunol.
1997;
45
315-321
- 14
Deuschl H.
Immunoglobulins in nasal secretion with special reference to IgE. II. Seasonal studies
of Timothy-specific IgE-antibody in patients with allergic rhinitis.
Int Arch Allergy Appl Immunol.
1976;
52
376-383
- 15
Marcucci F, Sensi L G, Migali E. et al .
Eosinophil cationic protein and specific IgE in serum and nasal mucosa of patients
with grass-pollen-allergic rhinitis and asthma.
Allergy.
2001;
56
231-236
- 16
Lin H, Boesel K M, Griffith D T. et al .
Omalizumab rapidly decreases nasal allergic response and FceRI on basophils.
J Allergy Clin Immunol.
2004;
113
297-302
- 17
Wenzel S, Bousquet J, Freeman P. et al .
Factors predictive of response to omalizumab therapy in patients with moderate-to-severe
allergic asthma.
J Allergy Clin Immunol.
2002;
109
A458
- 18
Casale T B, Bernstein I L, Busse W W. et al .
Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis.
J Allergy Clin Immunol.
1997;
100
110-121
- 19
Prussin C, Griffith D T, Boesel K M. et al .
Omalizumab treatment downregulates dendritic cell FcepsilonRI expression.
J Allergy Clin Immunol.
2003;
112
1147-1154
- 20
Kroegel C, Mock B, Reißig A. et al .
Antikörper bei allergischen Erkrankungen. Selektive Hemmung IgE-vermittelter Reaktionen
durch humanisierte Anti-IgE-Antikörper.
Arzneimittelth.
2002;
20
226-237
- 21
Lodrup-Carlsen K C, Halvorsen R, Ahlstedt S. et al .
Eosinophil cationic protein and tidal flow volume loops in children 0 - 2 years of
age.
Eur Respir J.
1995;
8
1148-1154
- 22
Walker S, Monteil M, Phelan K. et al .
Anti-IgE for chronic asthma.
Cochrane Database Syst Rev.
2003;
(3)
CD003559
Prof. Dr. med. Dr. rer. nat. Claus Kroegel
Pneumologie & Allergologie/Immunologie · Medizinische Klinik I, Friedrich-Schiller-Universität
Erlanger Allee 101
07740 Jena
Email: claus.kroegel@med.uni-jena.de
